high target affinity and specificity of vegf inhibitors is driving the Vascular Endothelial Growth Factor (Vegf) Inhibitors Market

Latest News:- Vascular Endothelial Growth Factor (Vegf) Inhibitors Market: Oncology is expected to lead the Application segment during 2024-2028

Technavio analyzes that the Vascular Endothelial Growth Factor (Vegf) Inhibitors Market is expected to grow at a CAGR of 8.09% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 11668.1 million.There are various factors that contribute to the growth of the market. VEGF inhibitors are distinguished by their high target affinity and specificity, making them highly effective in the treatment of various vascular diseases. These inhibitors selectively bind to Vascular Endothelial Growth Factor (VEGF), thereby inhibiting its interaction with receptors on the surface of endothelial cells. This results in the suppression of angiogenesis, or the formation of new blood vessels, which is a key process in the development of several pathologies, including age-related macular degeneration, diabetic retinopathy, and cancer. The specificity and high affinity of VEGF inhibitors make them valuable therapeutic agents in the management of these conditions.

The VEGF inhibitors market holds significant potential in the oncology sector, given that most approved VEGF inhibitors are indicated for oncology applications. In 2023, the oncology segment dominated the market, accounting for the largest share, and this trend is anticipated to continue through 2028. The segment's growth can be attributed to the rising incidence of various cancers worldwide, including breast cancer, lung cancer, bronchus cancer, melanoma, and pancreatic cancer. As a result, numerous companies, such as Molecular Partners, are investing heavily in research and development of oncology candidates like MP0250 to address the substantial unmet need in cancer treatment. 

Know which region is leading the market growth by requesting a sample report

Vascular Endothelial Growth Factor (Vegf) Inhibitors Market Segmentation

• Application
  • Oncology
  • Ophthalmology
• Type
  • VEGF-A inhibitor
  • VEGF-B inhibitor
  • VEGF-C inhibitor
  • VEGF-D inhibitor
• Geography
  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

Top Performing Companies

As per our research findings, here are some of the key competitors that are leading the industry

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca Plc
• Bausch Health Companies Inc.
• Bayer AG
• Bristol Myers Squibb Co.
• Clovis Oncology Inc.
• Eisai Co. Ltd.
• Eli Lilly and Co.
• Exelixis Inc.
• F. Hoffmann La Roche Ltd.
• LG Chem Ltd.
• Merck and Co. Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.
• Viatris Inc.
• Xbrane Biopharma AB

Find out what is trending in the market by accessing the free PDF report

Research Analysis Overview

The Vascular Endothelial Growth Factor (VEGF) inhibitors market is witnessing significant growth due to the pipeline analysis of new protein-based therapies for various indications. These inhibitors play a crucial role in preventing angiogenesis, the formation of new blood vessels, which is a key process in cancer formation and ophthalmic conditions like macular edema and retinal vein occlusion. Notable biopharma firms like Roche's Avastin have dominated the market for cancer indications, including ovarian, cervical, colon and rectum, prostate, breast, lung, and bronchus. However, the patent cliff and the emergence of biosimilar drugs pose challenges to market growth. Anti-VEGF therapeutics continue to be a focus area for research and development in cancer and eye care.

Market Research Overview

The Vegf inhibitors market is a significant segment of the global pharmaceuticals industry, focusing on the development and production of drugs that inhibit the Vascular Endothelial Growth Factor (Vegf) protein's role in angiogenesis, or the formation of new blood vessels, which is crucial in cancer formation. Key players in this market include Roche's Avastin and Genentech's Tecentriq. The market's growth is driven by the increasing prevalence of cancer, particularly in the aging population. By 2050, approximately one-quarter of the US and European populations are projected to be over 60 years old, increasing the demand for cancer treatments. Technavio's market analysis calculates the global pharmaceuticals market size based on the combined revenue generated by manufacturers and providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. The market's growth will be fueled by the rising prevalence of cancer and an aging population, leading to a higher demand for cancer treatments.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Reasons to Consider Purchasing Technavio Market Research Report

• Current Market Insights: Our reports offer valuable information on the latest market intelligence, competitor strategies, trends, industry changes, customer preferences, and forecasted market opportunities to aid in informed business decisions.


• Extensive Experience: With over 20 years in market research, Technavio is a trusted name, having published more than 21,000 reports across various industries and regions.


• High ROI Through In-Depth Research: Technavio specializes in tailored market research reports to meet specific business needs, exploring particular markets, product segments, and demographics. We are also recognized for delivering significant returns on investment through our comprehensive data collection at affordable prices.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/